Remidio’s Revolutionary AI on a smartphone for Referable Diabetic Retinopathy (DR) Receives EU MDR Class II Regulatory Approval
World’s first Smartphone based offline AI expands geographical scope to deliver convenience and increase access to DR screening. Remidio has received CE mark approval for its Medios AI, to detect Referable DR. This approval closely follows the nod the AI received from Singapore’s Health Sciences Authority (HSA), assuring compliance with the highest standards. DR is […]
